Determine if cilostazol improves symptoms and NTproBNP levels (heart failure blood marker) in
heart failure with preserved ejection fraction (HFpEF) - a prevalent syndrome without
targeted evidence-based treatment.
This will be assessed in a prospective 1-month single blinded study with 2 cross-overs n-of-1
study design with placebo and cilostazol